FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097804679> ?p ?o ?g. }

• W3097804679 endingPage "638" @default.
• W3097804679 startingPage "631" @default.
• W3097804679 abstract "Calcification propensity is associated with the risk for cardiovascular events and death in end-stage renal disease patients. Here we investigated the effect of lowering serum phosphate with oral phosphate binder therapy on calcification propensity.We performed an open-label, randomized, controlled, crossover study in chronic haemodialysis patients with hyperphosphataemia. Patients (n = 39) were randomized in a 1:1 ratio to either low-dose (250 mg/day) sucroferric oxyhydroxide (SO) followed by high-dose (2000 mg/day) SO or vice versa, with washout phases before and after SO treatment. The primary endpoint was changed in calcification propensity as measured by calciprotein particle formation time (T50 test) between washout and high-dose SO treatment in patients with ≥85% adherence to the prescribed SO dose (per-protocol analysis).In the primary per-protocol analysis (n = 28), 2000 mg/day SO treatment resulted in a mean increase in T50 of 66 min (95% CI 49-84 min, P < 0.0001), from 243 ± 63 to 309 ± 74 min compared with phosphate binder washout. Serum phosphate decreased from 2.28 ± 0.5 to 1.63 ± 0.43 mmol/L (P < 0.0001). SO at 250 mg/day did not influence T50 (P = 0.4) or serum phosphate concentrations (P = 0.9) compared with phosphate binder washout. The secondary intention-to-treat analysis (n = 39) showed similar results: an increase in T50 of 52 min (95% CI 31-74 min, P < 0.0001) and a decrease in serum phosphate from 2.18 ± 0.5 to 1.64 ± 0.46 mmol/L. No major adverse cardiovascular event, case of calciphylaxis or death occurred during the study.Phosphate binder treatment with SO improves serum calcification propensity of haemodialysis patients and might lead to improved outcomes." @default.
• W3097804679 created "2020-11-09" @default.
• W3097804679 creator A5011188514 @default.
• W3097804679 creator A5044033798 @default.
• W3097804679 creator A5050872462 @default.
• W3097804679 creator A5052805356 @default.
• W3097804679 creator A5057405792 @default.
• W3097804679 creator A5057839812 @default.
• W3097804679 creator A5079506605 @default.
• W3097804679 creator A5083103436 @default.
• W3097804679 creator A5086157063 @default.
• W3097804679 creator A5088731678 @default.
• W3097804679 date "2020-10-28" @default.
• W3097804679 modified "2023-10-12" @default.
• W3097804679 title "The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial" @default.
• W3097804679 cites W1178989217 @default.
• W3097804679 cites W1823050816 @default.
• W3097804679 cites W1982605543 @default.
• W3097804679 cites W2030174339 @default.
• W3097804679 cites W2056694775 @default.
• W3097804679 cites W2069001075 @default.
• W3097804679 cites W2101403851 @default.
• W3097804679 cites W2107207648 @default.
• W3097804679 cites W2108786753 @default.
• W3097804679 cites W2117116215 @default.
• W3097804679 cites W2122037712 @default.
• W3097804679 cites W2129282190 @default.
• W3097804679 cites W2136133622 @default.
• W3097804679 cites W2136628690 @default.
• W3097804679 cites W2150709875 @default.
• W3097804679 cites W2154497747 @default.
• W3097804679 cites W2158561625 @default.
• W3097804679 cites W2185799355 @default.
• W3097804679 cites W2560519247 @default.
• W3097804679 cites W2562981088 @default.
• W3097804679 cites W2607031541 @default.
• W3097804679 cites W2771269475 @default.
• W3097804679 cites W2805210199 @default.
• W3097804679 cites W2842564884 @default.
• W3097804679 cites W2888344409 @default.
• W3097804679 cites W2889032678 @default.
• W3097804679 cites W2936869448 @default.
• W3097804679 cites W2944570751 @default.
• W3097804679 cites W2982478970 @default.
• W3097804679 cites W4211140718 @default.
• W3097804679 cites W4234582290 @default.
• W3097804679 cites W4252418603 @default.
• W3097804679 doi "https://doi.org/10.1093/ckj/sfaa154" @default.
• W3097804679 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7886583" @default.
• W3097804679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33623689" @default.
• W3097804679 hasPublicationYear "2020" @default.
• W3097804679 type Work @default.
• W3097804679 sameAs 3097804679 @default.
• W3097804679 citedByCount "11" @default.
• W3097804679 countsByYear W30978046792021 @default.
• W3097804679 countsByYear W30978046792022 @default.
• W3097804679 countsByYear W30978046792023 @default.
• W3097804679 crossrefType "journal-article" @default.
• W3097804679 hasAuthorship W3097804679A5011188514 @default.
• W3097804679 hasAuthorship W3097804679A5044033798 @default.
• W3097804679 hasAuthorship W3097804679A5050872462 @default.
• W3097804679 hasAuthorship W3097804679A5052805356 @default.
• W3097804679 hasAuthorship W3097804679A5057405792 @default.
• W3097804679 hasAuthorship W3097804679A5057839812 @default.
• W3097804679 hasAuthorship W3097804679A5079506605 @default.
• W3097804679 hasAuthorship W3097804679A5083103436 @default.
• W3097804679 hasAuthorship W3097804679A5086157063 @default.
• W3097804679 hasAuthorship W3097804679A5088731678 @default.
• W3097804679 hasBestOaLocation W30978046791 @default.
• W3097804679 hasConcept C126322002 @default.
• W3097804679 hasConcept C126894567 @default.
• W3097804679 hasConcept C142724271 @default.
• W3097804679 hasConcept C168563851 @default.
• W3097804679 hasConcept C185592680 @default.
• W3097804679 hasConcept C203092338 @default.
• W3097804679 hasConcept C204787440 @default.
• W3097804679 hasConcept C27081682 @default.
• W3097804679 hasConcept C2776036575 @default.
• W3097804679 hasConcept C2777132085 @default.
• W3097804679 hasConcept C2777425297 @default.
• W3097804679 hasConcept C2778653478 @default.
• W3097804679 hasConcept C2779148903 @default.
• W3097804679 hasConcept C2780309369 @default.
• W3097804679 hasConcept C55493867 @default.
• W3097804679 hasConcept C71839028 @default.
• W3097804679 hasConcept C71924100 @default.
• W3097804679 hasConcept C87813604 @default.
• W3097804679 hasConcept C90924648 @default.
• W3097804679 hasConceptScore W3097804679C126322002 @default.
• W3097804679 hasConceptScore W3097804679C126894567 @default.
• W3097804679 hasConceptScore W3097804679C142724271 @default.
• W3097804679 hasConceptScore W3097804679C168563851 @default.
• W3097804679 hasConceptScore W3097804679C185592680 @default.
• W3097804679 hasConceptScore W3097804679C203092338 @default.
• W3097804679 hasConceptScore W3097804679C204787440 @default.
• W3097804679 hasConceptScore W3097804679C27081682 @default.
• W3097804679 hasConceptScore W3097804679C2776036575 @default.
• W3097804679 hasConceptScore W3097804679C2777132085 @default.

• next